Celldex Therapeutics, Inc. is a biopharmaceutical company that develops therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Clinical programs include Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, being developed for chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. Another candidate, CDX-622, is a bispecific antibody for inflammatory diseases that targets two complementary pathways driving chronic inflammation, neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Kodiak, Celldex, Rapport and Vaxcyte Face Key Fall Clinical Readouts
Four clinical-stage biotech companies are approaching potentially important mid- to late-stage data readouts this fall, with outcomes that could reshape their pipelines and valuations. Kodiak Sciences is on track to report top-line data this month from the phase III DAYBREAK study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 for treatment-naïve wet age-related macular degeneration against Regeneron's Eylea, targeting a roughly $15-billion anti-VEGF market. Celldex Therapeutics expects a September/October 2026 top-line readout from its phase III EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in chronic spontaneous urticaria, with 1,939 patients enrolled and a planned regulatory submission in 2027. Rapport Therapeutics is targeting October 2026 for phase II results on RAP-219 in bipolar mania, while Vaxcyte expects top-line safety, tolerability and immunogenicity data from the phase III OPUS-1 study of its 31-valent pneumococcal conjugate vaccine VAX-31 by the end of October 2026. Among the four, Kodiak carries a Zacks Rank #4 (Sell), while Celldex, Rapport and Vaxcyte each hold a Zacks Rank #3 (Hold).
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) Technology
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Technology
CLDX · Technology · Neutral Phase III EMBARQ-CSU studies of barzolvolimab in chronic spontaneous urticaria await fall top-line readout, a binary pipeline event
KOD · Technology · Neutral Phase III DAYBREAK data for Zenkuda/KSI-501 in wet AMD due this month, a binary pipeline event
PCVX · Technology · Neutral Phase III OPUS-1 safety and immunogenicity data for VAX-31 pneumococcal vaccine expected by end of October 2026
RAPP · Technology · Neutral Phase II results for RAP-219 in bipolar mania targeted for October 2026, a binary pipeline event
Celldex Therapeutics Could Be 130% Undervalued After Second Quarter Results
Celldex Therapeutics released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. The stock has climbed strongly over the past year, with a year-to-date share price return of 54.42% and a one-year total shareholder return of 101.89%, while the recent 90-day gain of 29.21% suggests momentum has been building into the latest earnings update. On Simply Wall St's numbers, Celldex Therapeutics trades on a price-to-book ratio of 4.6x, which is expensive relative to the broader US Biotechs industry average of 2.5x and a peer group average of 4.4x, signaling a premium valuation. However, using the SWS DCF model, Celldex Therapeutics at $41.71 is trading below an estimated future cash flow value of $96.10, which points to a very large implied discount. The company faces key risks including ongoing clinical trial uncertainty and a current net loss of $300.549 million.
Celldex Therapeutics Reports Widening Losses and Minimal Revenue in Second Quarter 2026
Celldex Therapeutics reported second-quarter 2026 revenue of just US$0.022 million and a net loss of US$73.5 million, with loss per share from continuing operations reaching US$0.94. For the first half of 2026, revenue totaled only US$0.037 million while the net loss grew to US$152.19 million, underscoring the cost intensity of its operations relative to minimal reported revenue. The company's investment narrative remains heavily dependent on its immunology pipeline, particularly barzolvolimab in chronic spontaneous urticaria, with key catalysts tied to late-stage data readouts and the Phase 3 timeline. Despite the widening losses, the share price has moved strongly year to date, suggesting the market is prioritizing trial progress over near-term financials, though the margin for disappointment appears tighter.
Celldex's Barzolvolimab Fails Phase 2 Prurigo Nodularis Study
Celldex reported that its Phase 2 study of barzolvolimab in prurigo nodularis did not meet the primary endpoint or key secondary endpoints. The randomized, double-blind, placebo-controlled trial evaluated two dose levels in patients with moderate to severe PN, but no meaningful improvement versus placebo was observed through week 24. Celldex will discontinue the Phase 2 study in PN, though barzolvolimab demonstrated a favorable safety and tolerability profile. The company noted that barzolvolimab has produced best-in-disease data in chronic spontaneous urticaria, symptomatic dermographism, and cold urticaria, and Phase 3 trials in CSU are expected to report data early this fall. Celldex shares fell 3.95% in after-hours trading to $34.25.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▼Technology
CLDX · Technology · Negative Phase 2 study of barzolvolimab in prurigo nodularis failed to meet primary and key secondary endpoints, leading to discontinuation of the study.
Celldex initiates CFO search as Sam Martin plans 2027 retirement
Celldex has begun searching for a new chief financial officer after Senior Vice President and CFO Sam Martin informed the company of his plans to retire in 2027. Martin will remain as CFO through March of 2027 to support a smooth transition. He has served as CFO since 2017 and has been part of the Celldex finance team since April 2009. The immunology company is advancing its lead candidate barzolvolimab through Phase 3 trials in chronic spontaneous urticaria and other indications, with topline data expected later this year and a planned BLA submission in 2027. As of March 31, 2026, Celldex held $451.5 million in cash, cash equivalents, and marketable securities, and together with proceeds from an April public offering, it expects to fund planned operations through 2028.
UBS Raises Celldex Price Target to $45 on Barzolvolimab Phase 3 Outlook
UBS raised its price target on Celldex Therapeutics to $45 from $38 while maintaining a Buy rating, citing a favorable development outlook for barzolvolimab's Phase 3 chronic spontaneous urticaria program that could support a potential approval in 2027. Celldex also presented updated Phase 2 findings at the European Academy of Allergy and Clinical Immunology Annual Meeting showing barzolvolimab provided rapid and sustained improvements in angioedema symptoms, with benefits lasting seven months after dosing ended. The results reinforce barzolvolimab's potential to move chronic spontaneous urticaria treatment toward disease modification and support ongoing Phase 3 trials.
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs
The chronic spontaneous urticaria market across the seven major markets reached approximately 2 billion dollars in 2025, with the United States holding the largest share. Total diagnosed prevalent cases of chronic urticaria in those markets were about 4.8 million in 2025 and are expected to rise by 2036. Key companies advancing new therapies include Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, and Otsuka Holdings through Taiho Pharmaceutical. Promising pipeline candidates such as barzolvolimab, rilzabrutinib, briquilimab, EVO756, BLU-808, ARS-1, bexobrutideg, INF904, and TAS5315 are in clinical development, while recent approvals of DUPIXENT and RHAPSIDO have already broadened treatment options beyond traditional anti-IgE biologics.
QURE Surges 81% on FDA Reversal, Spotlighting Five Biotech Catalysts
UniQure NV shares surged 81% on Wednesday after the FDA reversed course and accepted its Huntington's disease therapy data for an accelerated approval filing, a move flagged days earlier by unusual options activity. The stock jumped from a prior close of $26.99 to an intraday high of $48.88, closing in the high $47s, after the agency indicated AMT-130 data would support a filing, reversing a March decision that had sent shares from $25 to $9. The rally was preceded by weeks of institutional call buying, including a multi-million dollar order on June 9 across October 33 and 43 strikes, which a trader highlighted as a signal of smart-money positioning. The same catalyst-driven approach is now being applied to five other biotech names: Celcuity faces a July 17 FDA decision for gedatolisib in breast cancer, with major funds holding through a prior drawdown; Ionis has two PDUFA dates—June 30 for olezarsen and September for zilganersen—though insider selling of $57.8 million warrants caution; Celldex awaits Phase 3 barzolvolimab data in chronic spontaneous urticaria in Q4 next year, with a Phase 2 readout this summer, but rich options premiums keep it on watch; Travere already won approval for FILSPARI in FSGS in April and is now a commercial execution and takeout story with Overweight ratings from Citi and JPMorgan; and Replimune resubmitted its BLA for RP1 after a second Complete Response Letter, with FDA alignment on May 29, drawing Baker Bros and other funds, though it remains the lowest-conviction name on the board.
United States